Ionis Pharmaceuticals has reduced the annual wholesale price of its triglyceride-lowering drug Tryngolza to $40,000 from $595,000, aiming to compete effectively ahead of a potential FDA approval for severe hypertriglyceridemia (sHTG) expected by June 30. This pricing adjustment aligns with insurance payer cycles and positions Tryngolza below a competitor's $60,000 price while reflecting strong clinical outcomes. Analysts view this as a strategic move that could boost revenue forecasts and expand the drug's market beyond its current rare disease indication. The FDA decision could unlock significant commercial growth for Ionis, with analysts maintaining a positive outlook on the stock.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Immuron Limited announced a 6% increase in global sales for FY26, reaching AUD$7.7 million, driven by a 10% rise in Australian sales and significant growth in Canada and the US markets. The growth in Australia is attributed to enhanced digital market...
GRAVITY Co., Ltd. has officially launched Ragnarok: The New World, an open-world MMORPG based on the popular Ragnarok IP, in Southeast Asia on July 16, 2026. The game is available on both Mobile (Google Play and Apple App Store) and PC (official webs...
Zymeworks Inc. will release its second quarter 2026 financial results after market close on August 6, 2026. The company will not hold an earnings call following the release due to its pending acquisition of Theravance Biopharma. This acquisition will...
Global Net Lease, Inc. announced it will release its financial results for the second quarter ending June 30, 2026, on August 5 after the NYSE closes. The company will hold a conference call and webcast on August 6 at 11:00 a.m. ET to discuss the res...
